Live Breaking News & Updates on Infigratinib|Page 2

Stay updated with breaking news from Infigratinib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BridgeBio Pharma, Inc.: BridgeBio Pharma's Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ (infigratinib) for Patients with Cholangiocarcinoma

Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring ....

United States , Hong Kong , Bio Pharma , Linkedinand Vimeo , Susan Moran , Stacie Lindsey , Paola Bonvicini , Milind Javle , Paul Rittman , Ireland Helsinn Birex Pharmaceuticals Ltd , Helsinn Therapeutics Us Inc , Us Helsinn Therapeutics Inc , Oncology Center , Swiss Pharma Company , Therapeutics Inc , Bridgebio Pharma Inc , Helsinn Group Media Contact , European Union , B Future Health Fund , Helsinn Group , Helsinn Investment Fund , University Of Texas Md Anderson Cancer Center , Drug Administration , China Helsinn Pharmaceuticals Beijing Co Ltd , Group Head Of Communication , Cholangiocarcinoma Foundation ,